Overview
To describe and compare the symptom burden in cancer patients with concurrent diagnosis of heart failure (HFrEF compared to HFpEF).
Description
The investigators will conduct a symptom assessment at study enrollment on cancer participants with a concurrent diagnosis of HF (HFrEF and HFpEF) using the MD Anderson Symptom Inventory- Heart Failure (MDASI-HF) and PROMIS Instruments (Fatigue, Dyspnea, and Sleep Disturbance).
The investigators will also describe and compare the health-related quality of life using the European Organization for Research and Training Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the measure of Quality of Life Short Form-12 (SF-12).
Eligibility
Inclusion Criteria:
- Age 18 years and older
- Individuals with a concurrent solid tumor cancer diagnosis
- Not receiving active cancer treatment except for those on maintenance (i.e., Selective ER modulators (SERMs)[Tamoxifen], Aromatase inhibitors (Anastrozole, Letrozole, Exemestane), Ovarian suppression therapy (GnRH Agonists [Leuprolide], Androgen deprivation therapy for prostate cancer
- Completed cancer treatment at least 3 months and up to 3 years before study enrollment.
Therapy
- Able to read, speak and consent in English
- Ability to understand and the willingness to sign a written informed consent document
- Diagnosis of heart failure, confirmed by echocardiogram, MUGA, or cardiac catheterization
- Internet access via smart phone, tablet, a computer, or another device with the capacity to 1) download the Fitbit App and 2) complete electronic study assessments via REDCap.
Exclusion Criteria:
- Participants undergoing active cancer treatment.
- Inability to provide consent in the medical record, such as cognitively impaired individuals.